Pediatric Rheumatology

Is Complementary and Alternative Healthcare Use Associated with Better Outcomes in Children with JIA?
K. Toupin-April, D. Ehrmann Feldman, M.V. Zunzunegui, M. Descarreaux, P. Malleson, C.M. Duffy. 2302

Serum Osteopontin as a Predictive Marker of Responsiveness to MTX in JIA
L. Masi, L. Ricci, F. Zulian, et al. 2308

Images in Rheumatology

Giant Cell Arteritis Involving the Mesenteric Arteries
M.A. Azeez, P. Browne, P. O’Connell, D. Roysten 2314
Dropped-head Syndrome Due to High-dose Irradiation
C. Appels, R. Goekoop 2316
So-called Lateral Meniscal Cyst
G. Mahe, C. Chevalier, J. Caroff, G. Leftheriotis 2317


Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct

Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome

Developing a Standardized Definition for Disease “Flare” in RA (OMERACT 9 Special Interest Group)
C.O. Bingham III, C. Pohl, T.G. Woodworth, et al. 2335

Outcome Domains for Studies of Acute and Chronic Gout
H.R. Schumacher, W. Taylor, L. Edwards, et al. 2342

Progress in Measurement Instruments for Acute and Chronic Gout Studies

Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
D. Khanna, O. Distler, J. Avouac, et al. 2356

Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
P.A. Merkel, K. Herlyn, A.D. Mahr, et al. 2362

Letters

Multifocal Bone Infarcts and Buprenorphine: Association or Coincidence?
M. Laroche, A. Brouchet, B. Mazières 2369
Calciphylaxis in the Absence of Renal Disease: Secondary Hyperparathyroidism and SLE
J.J. Zechlinski, J.R. Angel 2370
Is E148Q a Benign Polymorphism or a Disease-causing Mutation?
D. Marek-Yagel, I. Bar-Joseph, E. Pras, Y. Berkun 2372

Meetings in Rheumatology xvi